Background: Capecitabine and cyclophosphamide are active in patients with advanced breast cancer, have nonoverlapping toxic effects and synergy pre-clinically. We explored the efficacy and toxic effect of an all-oral combination of capecitabine with cyclophosphamide versus capecitabine alone in a multicentre, randomized, phase II study. Results: Eighty-two patients were randomized. There was no complete response. The proportions with partial response were 36% on C and 44% on CCy, a difference of 7.9% [95% confidence interval (CI) −13.4 to 29.1]. Significant toxic effect was uncommon: grade ≥3 diarrhoea in 4 (10%) versus 1 (3%) patients; grade ≥3 fatigue in 2 (5%) versus 5 patients (13%) and grade ≥2 hand-foot syndrome in 7 (17%) versus 11 (28%) patients receiving C versus CCy, respectively. Median progression-free survival was 3.1 months on C and 6.9 months on CCy, not significantly different statistically. There was no difference in overall survival.
introduction
Capecitabine has substantial activity in a wide range of solid tumours, including metastatic breast cancer, with response rates of ∼30% initially or after failure of other cytotoxics. It has shown similar efficacy to intravenous CMF [1] and paclitaxel [2] and has shown superior overall survival compared with classical oral CMFP [3] .
Capecitabine is an orally bioavailable, rationally designed prodrug of 5-fluorouracil (5FU) [4] . It is rapidly absorbed by the gut, with ∼80% bioavailability. It is inactive in the parent form, undergoing a three-step enzymatic conversion to the active metabolite. Initially capecitabine is hydrolysed in the liver by a hepatic carboxyl esterase to 5 0 -deoxy-5-fluorocytidine and then to 5 0 -deoxy-5-flurouridine by cytidine deaminase in liver and tumour tissue [4, 5] . The final step involves conversion to 5FU by thymidine phosphorylase (dThdPhase) found in liver, intestine and tumour tissue [4, 5] . Thymidine phosphorylase is expressed in much higher concentrations in tumour tissues of breast, gastrointestinal (GI) tract and head and neck origin [6] , suggesting particular potential benefit in these tumour types. Clinical studies using capecitabine have shown the resulting 5FU concentrations in tumour tissue to be 3.5 times greater than in normal tissue and 20 times greater than in serum [7] .
Data suggest that several cytokines (IL1-α, TNF-α and interferon-γ), growth factors (β-FGF, PDGF), hypoxia, radiation and several cytotoxics (taxanes, mitomycin C and cyclophosphamide) up-regulate thymidine phosphorylase in mouse mammary tumour tissue, but not in liver or intestine [8, 9] . The up-regulation with cyclophosphamide occurs following oral administration as well as intravenous administration [8] and the combination of cyclophosphamide and capecitabine has shown synergistic anti-tumour activity without potentiation of toxic effect [8] . In contrast, cyclophosphamide and 5FU are only additive [8] . A capecitabine/cyclophosphamide combination clearly merits further investigation.
Oral therapy has several potential advantages in treating cancer, especially when the aim of therapy is palliative, as it is in metastatic breast cancer. Intravenous injections are a major source of discomfort and stress to patients [10, 11] and patients have reported a strong preference for oral therapy [12] [13] [14] provided efficacy is not compromised [12, 15, 16] . This is particularly pertinent for schedule-dependent cytotoxics, such as 5FU, where prolonged administration has been shown superior to bolus administration [17] . Other potential advantages of oral therapy include greater patient convenience with fewer and shorter visits to hospital, less anxiety associated with administration [13, 15] and lower cost to patient [18] and provider [19] [20] [21] [22] [23] . These possible benefits must be balanced against the potential for reduced compliance [14, 16] , especially in patients who suffer gastrointestinal toxic effect, and variable bioavailability. While much variability in bioavailability is inherent [24] [25] [26] [27] , compliance can be improved by education [28] .
In addition to the benefits of oral therapy for the patient, oral therapy permits flexibility and adaptability in coping with toxic effect as well as significant reduction in use of resources, allowing the treatment of more patients [19, 20, 29] . This aspect will be helpful to health professionals and may be particularly attractive to health managers [29] .
With this background, we sought to develop an all-oral cytotoxic regimen for metastatic breast cancer that might prove more effective than capecitabine alone.
patients and methods

patients
Patients were recruited from all six New Zealand major cancer centres between April 2004 and February 2007. Patients were eligible for the study if they had histological or cytological evidence of breast carcinoma locally advanced or metastatic measurable disease as defined by the RECIST criteria [30] , were at least 18 years of age and had given written informed consent. Patients had to have adequate baseline bone marrow reserve and liver function, a calculated creatinine clearance (Cockroft and Gault) >50 ml/min, WHO performance status 0-3 and have had no more than one prior chemotherapy regimen for advanced disease. Patients with HER2-positive tumours were eligible, if they had had trastuzumab as first-line therapy for metastatic disease (eight patients), as such patients are not eligible for government funded anti-HER2 directed therapy 'beyond progression of disease' on first-line trastuzumab in New Zealand or refused trastuzumab therapy (two patients declined injections). HER2 status was not known in 31% and 53% of patients in the single and combination arms, because the metastatic site was not amenable to biopsy and the primary tumour had not been tested. Patients were excluded if they were male, had brain and/or leptomeningeal disease, were pregnant or lactating, had been exposed to investigational drug therapy within 30 days before randomization or were receiving concurrent anti-cancer therapy. Patient and disease characteristics are shown in Table 1 .
After confirmation of eligibility patients were randomly allocated to capecitabine given continuously (666 mg/m 2 b.i.d. days 1-28) either alone (C) or with oral cyclophosphamide (100 mg/m 2 as a single daily dose on days 1-14 of a 28-day cycle) (CCy), using central web-based randomization.
The study was open label and randomization was blocked to ensure balance between treatment arms over time. The dose levels were chosen on the basis of a phase I dose-escalation study of the drug combination [31] . Treatment continued for a maximum of six cycles, or until disease progression, whichever occurred sooner. The primary outcome measure of efficacy was best overall tumour response measured according to the RECIST criteria [30] . However, since it was not possible to confirm a response until at least 2 months in some patients, because of resource constraints, unconfirmed response was used as the primary outcome and confirmed response was reported in the text. The proportion of patients who had a disease response on C versus CCy was compared using a 95% confidence interval (CI) for the difference. Proportions of patients who experienced an adverse event were compared using Fisher's exact test. Baseline prognostic factors were adjusted for, using logistic regression. Dose intensity was calculated as the proportion of the planned dose delivered over the time the patient remained on treatment. Progression-free survival and overall survival were compared using Kaplan-Meier survival curves and log-rank tests. The date of progression refers to clinical, including radiological progression. Safety was assessed using the Common Terminology Criteria for Adverse Events v 3.0 (CTCAE) of the National Cancer Institute (reporting proportions of patients with grade 3 or higher toxic effect, with the exception of hand-foot syndrome, where grade 2 was included). Intention-to-treat analyses were used for all comparisons with the exception of one patient who withdrew consent before treatment.
The study was designed with three decision regions for the estimated treatment effect (observed difference in tumour response rate between experimental and control arms) [32] . Calculations assumed a true tumour response rate of 30% in the control arm (C) and 50% in the experimental arm (CCy):
Region 1: if the estimated treatment effect was ≤7.6% we would conclude that CCy is unlikely to be superior to C alone, with a 12.5% chance of a false negative conclusion. Region 2: if the estimated treatment effect was ≤20% but >7.6% we would conclude that the evidence in favour of CCy over C was sufficiently promising to warrant further investigation in a larger trial. Region 3: if the estimated treatment effect was >20% then we would conclude that there was evidence the proportion of patients achieving tumour response was higher on CCy than C, with a 2.5% chance of a false positive conclusion.
Overall, if the true response rates are 30% and 50% on C and CCy, respectively, there is an 87.5% chance that the study will recommend further investigation. If there is no true difference, there is a 2.5% chance of falsely concluding that CCy gives a higher tumour response rate. The recruitment target was 80 patients. (Figure 1 ). The treatment groups were broadly comparable in terms of baseline prognostic factors (Table 1) , but there were differences in hormone receptor status (ER or PR receptor positive in 71% of patients receiving C compared with 60% receiving CCy) and prior adjuvant chemotherapy (57% receiving C compared with 43% receiving CCy). One patient randomized to CCy withdrew from the study before starting treatment. All other patients were followed and included in the analyses.
There was no complete response observed in the study ( Table 2 ). The proportion of patients whose tumour showed a partial response was 36% on arm C and 44% on arm CCy, a difference of 7.9% (95% CI −13.4 to 29.1). This difference is in the middle region of the three-region design, indicating sufficient possibility that the combination CCy has superior efficacy to C alone to justify further investigation of the combination in a larger study. The treatment benefit remained after adjustment for baseline prognostic factors. Of the 15 partial responses achieved with C, 10 were confirmed after at least 4 weeks, as were 13 of the 17 partial responses achieved with CCy ( Table 2 ). As the difference in proportion with confirmed response (9.5%) is also within the middle region of the three-region design, the conclusion remains unchanged.
The median progression-free survival was 3.1 months for patients receiving C and 6.9 months for patients receiving CCy, but this difference was not statistically significant ( Figure 2A , P = 0.44). There was no difference in overall survival: median 12.8 months with C and 13.2 months with CCy ( Figure 2B , P = 0.72).
Thirty-eight percent of patients receiving C and 43% of patients receiving CCy completed all six cycles of treatment (Table 3 ). The main reason for withdrawal from treatment was progressive disease (77% of withdrawals from C and 53% from CCy), although six patients (23%) receiving C and five patients (24%) receiving CCy withdrew due to chemotherapy toxic effect. Two patients on the CCy arm died, one from progression of disease before the first response evaluation and original articles Annals of Oncology the other from pulmonary embolism, not thought due to treatment. The average dose intensity for the duration of treatment was 89% for patients receiving treatment with capecitabine alone and 84% for capecitabine and 94% for cyclophosphamide for patients receiving CCy (Table 3) .
The most common adverse events were grade 3/4 neutropenia [N = 3 (7%) with C and N = 13 (33%) with CCy, P = 0.005], febrile neutropenia [N = 1 (2%) with C and N = 4 (10%) with CCY], grade 2/3 hand-foot syndrome [N = 7 (17%) with C and N = 11 (28%) with CCy, P = 0.3], grade ≥3 fatigue [N = 2 (5%) with C and N = 5 (13%) with CCy, P = 0.3] and grade ≥3 diarrhoea [N = 4 (10%) with C and N = 1 (3%) with CCy] (Table 4) . Growth factor support was not used. Other grade 3 or 4 toxic effects were uncommon (see Table 4 ).
discussion
Although all chemotherapy for metastatic breast cancer is palliative, there is still a belief among some physicians and patients that more aggressive chemotherapy will produce better outcomes [14] [15] [16] 33] . Given this belief and the small population in New Zealand, we were aware that there may be difficulty accruing sufficient patients to this study. Hence, we planned this design to enable us to identify possibly effective therapy as efficiently as possible.
The difference in tumour response rate between CCy and C (7.9% and 9.5% in unconfirmed and confirmed responses, respectively) suggests a reasonable possibility that the combination of CCy is more effective than treatment with C alone. This hypothesis needs further testing in a larger trial.
We are not aware of any other randomized study comparing capecitabine with capecitabine plus cyclophosphamide in metastatic breast cancer, but several Japanese investigators [34] [35] [36] and a South West Oncology Group (SWOG) study [37] have combined oral fluoropyrimidines with cyclophosphamide. A European group [38] has combined lowdose capecitabine and cyclophosphamide with bevacizumab and Tominaga et al. [39] have compared doxifluridine with or without cyclophosphamide in the adjuvant therapy of early breast cancer.
Yoshimoto et al. [34] reported a phase II study of doxifluridine, an intermediate metabolite of capecitabine, with cyclophosphamide given first or second line in 94 assessable patients with metastatic breast cancer. Treatment comprised doxifluridine 1200 mg total dose and cyclophosphamide 100 mg total dose, each given daily for 14 days out of every 21 days, until disease progression. They reported a 60% response rate (17% CR, 43% PR; 65% first and 46% second line), a given for 14 days every 21 days as first-or second-line therapy for a median of six cycles in metastatic breast cancer. They reported a 36% response rate, including 65% in predominant liver disease and 40% in triple negative disease, a median progression-free survival of 6.6 months and a median overall survival of 22 months. More recently, in a similar phase II study, Yoshimoto et al. [36] treated 51 patients, of whom 45 were included in the efficacy analysis, using the same eligibility criteria and treatment regimen. At a median follow-up of 18 months, they reported a response rate of 44% and a median progression-free survival of 12.3 months. At this dose of capecitabine, the area under the curve of 5FU would be expected to be almost twice that produced by the doxifluridine dose in the previous study [34] by the same group [40] .
Schott et al. [37] presented the results of SWOG study S0430 at the 2010 Annual Meeting of the American Society of Clinical Oncology. Using a continuous low-dose schedule of cyclophosphamide (100 mg total dose, days 1-14) and capecitabine (1500 mg total dose, twice daily for 14 days on days 8-21), repeated every 21 days, they treated 96 patients with metastatic breast cancer and no more than two previous chemotherapy regimens. They reported a 36% response rate, with 5.9-month progression-free survival and 19.6-month overall survival, results remarkably similar to Tanaka et al. [35] We are aware of one other Japanese study of capecitabine and cyclophosphamide, each given continuously every day, with a response rate of 37%, but no further information is currently available (Suzuki et al., personal communication, October 2009).
A European group [38] have combined low-dose capecitabine (500 mg t.i.d.) with cyclophosphamide (50 mg daily), given continuously as metronomic therapy with bevacizumab (10 mg/kg) intravenously every 14 days. They reported a response rate of 48% and progression-free survival of 42 weeks.
In early node-positive breast cancer, Tominaga et al. [39] , using intermittent cycles, compared cyclophosphamide and doxifluridine to doxifluridine alone. Disease-free survival was improved by 5.3% by the combination therapy (P = 0.021) with the effect perhaps more apparent in younger women [DFS improved 10.3%, in women <50 years (P = 0.019) compared with 2.3% in women >50 years (ns)]. Overall survival was similar in both groups (P = 0.497).
There are several possible reasons for the plausible superiority of the combination therapy in the current study. First, the administered dose of capecitabine was similar in each arm, so patients randomized to CCy received more chemotherapy. The increased effectiveness may be explained by this greater dose of chemotherapy. Secondly, many studies have shown an increased disease response rate with combination therapy [33] although most have failed to show improved progression-free survival or overall survival, as in this study. Thirdly, cyclophosphamide given orally in the schedule used in this study is known to up-regulate dThdPase [8, 9] , with dramatically increased anti-tumour effect in the human breast MX-1 xenograft model. Hence, capecitabine may be working more efficiently as a cytotoxic, in addition to any cytotoxicity from cyclophosphamide.
It is known that both 5-fluorouracil and cyclophosphamide are anti-angiogenic in metronomic schedules [41] [42] [43] , and there is information that combinations of anti-angiogenic therapy are more beneficial than single drugs in vitro [41, 43] and perhaps in patients [38] , although the optimal doses for metronomic activity are not known [43] . It is possible that the current regimen of continuous capecitabine and intermittent cyclophosphamide would have exhibited greater antiangiogenic activity, than capecitabine alone.
The intermittent cyclophosphamide regimen in conjunction with continuous capecitabine led to practical problems in administration, especially when dose adjustment was required. It was somewhat difficult, when neutropenia occurred around Formal comparisons of proportions experiencing adverse events were made when the total number was over 5. This gave P = 0.005 for neutropenia, P = 0.253 for fatigue and P = 0.286 for hand-foot syndrome. [41, 42] or a more conventional intermittent schedule is uncertain. It is not known whether the established up-regulation of thymidine phosphorylase by chemotherapy is influenced by schedule. We plan pilot studies to explore these aspects. This study suggests that the all-oral combination of cyclophosphamide and capecitabine was relatively well tolerated and had apparent superiority over C alone. It provides justification for a larger, definitive study and the basis for further work refining the optimal schedule. 
